viewSilence Therapeutics PLC

Silence Therapeutics - Additional listing – correction

RNS Number : 2319K
Silence Therapeutics PLC
20 April 2020


The following amendment has been made to the 'PDMR Dealing and Additional Listing' announcement released on April 20, 2020 at 07:00 under RNS No 1150K:


The date Admission is expected to be effective is April 23, 2020.


All other details remain unchanged. The full amended text is shown below.


PDMR Dealing and Additional Listing

April 20, 2020


LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 119,414 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the Employee Share Option Scheme and the 2018 Long Term Incentive Plan . Of these, Dr. Rob Quinn, Chief Financial Officer, exercised 89,054 share options at a weighted average price of £1.23, the majority of which were awarded on him joining the Company three years ago.


Following this exercise Dr. Quinn holds a further 677,823 options in the Company.


Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on April 23, 2020. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.


The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 82,796,259. The Company holds no shares in Treasury.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them



Details of the person discharging managerial responsibilities (PDMR) / person closely associated



Rob Quinn



Reason for the notification


Position / status

Chief Financial Officer



Initial notification / Amendment

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Silence Therapeutics plc







Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument


Identification code

Exercise of share options under the Employee Share Option Scheme and the 2018 Long Term Incentive Plan



ISIN for Silence Therapeutics plc Ordinary Shares:




Nature of the transaction

Exercise of Options  


Prices(a) and volume(s)











Aggregated information

- Aggregated volume

- Price


89,054 options at weighted average price of £1.23


Date of the transaction

20 April 2020



Place of the transaction

Outside a trading venue





Silence Therapeutics plc

Iain Ross, Executive Chairman

Dr Rob Quinn, Chief Financial Officer



Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson


Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]


Tel: +44 (0) 20 3709 5700


Westwicke Partners

Peter Vozzo

[email protected]


 Tel: +1 (443) 213-0505


About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company's future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit: https://www.silence-therapeutics.com/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected].com or visit www.rns.com.

Quick facts: Silence Therapeutics PLC

Price: 437

Market: AIM
Market Cap: £361.95 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Silence Therapeutics - Proactive One2One Virtual Event

Rob Quinn, from Silence Therapeutics (LON:SLN) pitches the company to investors at the Proactive One2One Virtual Event. Silence develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can...

2 days, 4 hours ago